Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?
- PMID: 34183586
- DOI: 10.14309/ajg.0000000000001217
Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?
Comment on
-
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.Am J Gastroenterol. 2020 Oct;115(10):1617-1623. doi: 10.14309/ajg.0000000000000832. Am J Gastroenterol. 2020. PMID: 32852338 Free PMC article.
References
-
- Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol 2020;115(10):1617–23.
-
- Freedberg DE, Conigliaro J, Wang TC, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterology 2020;159(3):1129–31.e3.
-
- Shahid Z, Kalayanamitra R, McClafferty B, et al. COVID-19 and older adults: What we know. J Am Geriatr Soc 2020;68(5):926–9.
-
- Fujiwara Y, Higuchi K, Nebiki H, et al. Famotidine vs. omeprazole: A prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005;21(Suppl 2):10–8.
-
- Martinsen TC, Bergh K, Waldum HL. Gastric juice: A barrier against infectious diseases. Basic Clin Pharmacol Toxicol 2005;96(2):94–102.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
